Browsing Tag
Alnylam Pharmaceuticals
14 posts
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
Can RNA interference expand beyond rare diseases through Tenaya–Alnylam cardiovascular research? (NASDAQ: ALNY, NASDAQ: TNYA)
Tenaya Therapeutics and Alnylam Pharmaceuticals partner to discover RNAi drug targets for cardiovascular disease. Read what this biotech deal could mean.
Can Norgine turn Vir Biotechnology’s hepatitis D duo into a regional blockbuster? €550m deal signals big bet
Vir Biotechnology licenses its hepatitis D therapy to Norgine in a €550M deal. Find out what this means for commercialization, access, and biotech strategy.
Why Vir Biotechnology’s tobevibart and elebsiran combo may signal a breakthrough in hepatitis delta treatment
Vir Biotechnology’s hepatitis delta therapy shows 66% RNA clearance at 48 weeks. Find out why this could redefine treatment ahead of 2027 trial results.
Can Alnylam Pharmaceuticals’ vutrisiran reverse cardiac damage? HELIOS-B Phase 3 ATTR-CM trial says yes
New HELIOS-B data shows vutrisiran improves cardiac structure and kidney outcomes in ATTR-CM. Find out how Alnylam’s RNAi drug is reshaping treatment.
Can vutrisiran set a new first-line standard in ATTR-CM after HELIOS-B trial results?
Alnylam’s HELIOS-B data shows vutrisiran cuts GI events by up to 49% in ATTR-CM, reinforcing its case as a first-line therapy. Read the full analysis.
Alnylam Pharmaceuticals (NASDAQ: ALNY) to launch global Phase 3 trial of RNAi therapy zilebesiran in high-risk hypertension patients
Alnylam Pharmaceuticals (NASDAQ: ALNY) moves its RNAi drug zilebesiran into a global Phase 3 trial for hypertension after ESC 2025 data showed sustained blood pressure reductions.
How do Vutrisiran’s HELIOS-B results compare with historical standards in ATTR-CM treatment?
Alnylam’s vutrisiran reduces cardiovascular mortality and urgent heart failure visits in ATTR-CM, reinforcing AMVUTTRA’s first-line potential. Read key data now.
Foot Locker, DigitalBridge, and Regencell lead top gainers as US markets rally
Find out why Foot Locker, DigitalBridge, and biotech names led U.S. stock gainers on May 15, 2025, amid shifting economic signals and sector rebounds.
Skechers, BioCryst, FTAI Aviation lead U.S. stock gainers as investors shift focus to sector-specific catalysts
See which U.S. stocks surged on May 5, 2025, and why gold, biotech, and aviation names like Skechers, BioCryst, and FTAI Aviation outperformed the market.